Related Experiment Video
Updated: Aug 19, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector
F Dupont1, B Avalosse, A Karim
1Laboratoire d'Investigation Clinique et d'Oncologie Expérimentale, Unité d'Oncologie Moléculaire, Belgium.
Abstract:
A recombinant MVMp of the fibrotropic strain of minute virus of mice (MVMp) expressing the chloramphenicol acetyltransferase reporter gene was used to infect a series of biologically relevant cultured cells, normal or tumor-derived, including normal melanocytes versus melanoma cells, normal mammary epithelial cells versus breast adenocarcinoma cells, and normal neurons or astrocytes versus glioma cells. As a reference cell system we used normal human fibroblasts versus the SV40-transformed fibroblast cell line NB324K. After infection, we observed good expression of the reporter gene in the different tumor cell types, but only poor expression if any in the corresponding normal cells. We also constructed a recombinant MVMp expressing the green fluorescent protein reporter gene and assessed by flow cytometry the efficiency of gene transduction into the different target cells. At a multiplicity of infection of 30, we observed substantial transduction of the gene into most of the tumor cell types tested, but only marginal transduction into normal cells under the same experimental conditions. Finally, we demonstrated that a recombinant MVMp expressing the herpes simplex virus thymidine kinase gene can, in vitro, cause efficient killing of most tumor cell types in the presence of ganciclovir, whilst affecting normal proliferating cells only marginally if at all. However, in the same experimental condition, breast tumor cells appeared to be resistant to GCV-mediated cytotoxicity, possibly because these cells are not susceptible to the bystander effect. Our data suggest that MVMp-based vectors could prove useful as selective vehicles for anticancer gene therapy, particularly for in vivo delivery of cytotoxic effector genes into tumor cells.
Insights
Minute virus of mice (MVMp) vectors show selective gene expression and killing of tumor cells, sparing normal cells. This suggests MVMp
Area of Science:
- Oncolytic virotherapy
- Gene therapy vectors
- Molecular virology
Background:
- Minute virus of mice (MVMp) is a parvovirus with potential for targeted gene delivery.
- Developing selective cancer therapies remains a critical challenge in oncology.
Purpose of the Study:
- To evaluate the potential of MVMp-based vectors for selective anticancer gene therapy.
- To assess the efficiency of MVMp-mediated gene transduction and cytotoxicity in various tumor and normal cell types.
Main Methods:
- Recombinant MVMp vectors expressing reporter genes (CAT, GFP) and a cytotoxic gene (HSV-TK) were constructed.
- Infection of normal and tumor-derived cell lines (melanocytes, breast cancer, glioma, neurons, fibroblasts) with MVMp vectors.
- Assessment of reporter gene expression, gene transduction efficiency (flow cytometry), and ganciclovir-mediated cytotoxicity.
Main Results:
- MVMp vectors demonstrated significantly higher reporter gene expression and gene transduction in tumor cells compared to normal cells.
- Recombinant MVMp expressing herpes simplex virus thymidine kinase (HSV-TK) efficiently killed most tested tumor cells in the presence of ganciclovir.
- Breast tumor cells showed resistance to ganciclovir-mediated killing, potentially due to a lack of bystander effect.
Conclusions:
- MVMp-based vectors exhibit selective targeting of tumor cells, with efficient gene delivery and oncolytic potential.
- These vectors hold promise for in vivo delivery of cytotoxic effector genes in anticancer gene therapy.
- Further investigation is needed to address resistance mechanisms, such as in breast tumor cells.
Related Concept Videos
In-vitro Mutagenesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

